Form 4: ADMA Biologics COO Kaitlin Kestenberg-Messina Reports Stock Transactions
SEC Form 4 Filing
Kaitlin Kestenberg-Messina, COO and SVP, Compliance of ADMA Biologics, reports the withholding of shares to cover tax obligations upon the vesting of restricted stock units.
Summary
- On March 6, 2025, Kaitlin Kestenberg-Messina had 8,881 shares of common stock withheld by ADMA Biologics at a price of $16.91 to cover tax obligations related to vesting RSUs.
- Following this transaction, she beneficially owned 513,280 shares.
- On March 7, 2025, an additional 3,935 shares were withheld at $17.02, resulting in beneficial ownership of 509,345 shares.
- These shares include unvested RSUs granted on various dates and common stock owned reflecting prior net settlements of RSUs after tax withholdings.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions related to tax obligations, with no inherent positive or negative implications.
Industry Context
This Form 4 filing is a routine disclosure related to stock transactions by a company insider, which is a common occurrence in publicly traded companies.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they relate to tax obligations of an executive.
Key Dates
| Date | Description |
|---|---|
| 03/06/2025 | 8,881 shares of common stock withheld for tax obligations at $16.91 per share. |
| 03/07/2025 | 3,935 shares of common stock withheld for tax obligations at $17.02 per share. |
| 03/10/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.